RHYTHM PHARMACEUTICALS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+36.9% +$15M
$57M
Cost of Revenue↑+26.8% +$1M
$5M
R&D↑+2.1% +$865K
$42M
SG&A↑+50.8% +$19M
$57M
D&A
—
Operating Income↓-20.0% -$9M
$-53M
EBITDA↓-20.0% -$9M
$-53M
Interest Expense↓-15.3% -$832K
$5M
Interest Income
—
Other Income/Expense↓-10.5% -$540K
$5M
Pretax Income↓-20.0% -$9M
$-53M
Tax Provision↑+132.3% +$455K
$111K
Net Income↓-21.2% -$9M
$-53M
Operating Margin↑+29.3pts
-102.6%
Net Margin↑+28.1pts
-103.1%
Effective Tax Rate↓-1.0pts
-0.2%
Deferred Tax Liabilities
—
ETR (Continuing Operations)↓-0.1pts
-0.3%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-5.6pts
0.0%
ETR Foreign Differential (pp)
-0.3%
Operating Lease Cost
$302K
Revenue YoY Variation↓-35.7pts
36.9%
Income YoY Variation↓-20.1pts
-20.0%
Revenue QoQ Variation↓-14.2pts
11.6%
Income QoQ Variation↓-7.8pts
-16.2%